Spirulina and antiphospholipid syndrome.

APS pathophysiology

• Antibodies and thrombotic mechanisms: Anti-cardiolipin (aCL), anti-beta₂-glycoprotein I (anti-β₂GPI), and lupus anticoagulant (LA) antibodies act through multiple mechanisms: complement activation (C5b-9 deposition on endothelial cells), endothelial NOX2 activation generating superoxide and reducing NO bioavailability, platelet activation (pro-thrombotic state), and inhibition of anticoagulant proteins (annexin A5, protein C/S, tissue factor pathway inhibitor). Triple positivity (LA + aCL + anti-β₂GPI all positive) confers the highest thrombotic risk.
• Thrombotic vs obstetric APS: Thrombotic APS: recurrent DVT, PE, arterial thrombosis (stroke, MI). Treated with lifelong warfarin (target INR 2.5–3.5 for arterial APS, 2.0–3.0 for venous APS). Obstetric APS: recurrent miscarriage, stillbirth, pre-eclampsia. Treated with aspirin + LMWH in pregnancy.
• Endothelial NOX2: Anti-β₂GPI antibodies activate endothelial NOX2 via TLR4 co-receptor signalling. Phycocyanobilin’s NOX2 inhibition is mechanistically relevant to reducing endothelial activation in APS — though clinical evidence is absent. The warfarin interaction takes priority in practical management.

Warfarin: the critical interaction

• Vitamin K content of spirulina: Spirulina contains approximately 20–30 µg vitamin K per 10 g dry weight (primarily phylloquinone, vitamin K₁). This is a modest amount compared to leafy greens (e.g., spinach ~500 µg/100 g) but is meaningful in the context of consistent daily dosing. Warfarin competitively inhibits vitamin K epoxide reductase; any change in daily vitamin K intake shifts the competitive equilibrium and changes INR.
• Consistency rule: If taking spirulina on warfarin, the dose must be identical every day. Taking spirulina 5 days/week and skipping 2 days creates a cyclic INR fluctuation. Taking the same 5 g every day is equivalent to a consistent daily vitamin K intake and the INR stabilises at the new level. Never start spirulina without informing the anticoagulation clinic.
• Introduction protocol: Start at a low consistent dose (1 g/day for 1 week); check INR after 1 week. If INR is stable, increase to 2 g/day for 1 week, recheck INR. Continue stepwise to target dose with INR check at each step. Once stable at target dose, return to standard anticoagulation review intervals.
• Never vary the dose: If a day is missed, do not double the dose the following day. If dose is temporarily stopped (illness, surgery), inform anticoagulation clinic and check INR before resuming. The vitamin K consistency rule in APS on warfarin is the same as in any other warfarin context but carries higher stakes given the thrombotic risk of sub-therapeutic anticoagulation in APS.

Antiplatelet effects

• Spirulina has mild antiplatelet effects at ≥5 g/day (GLA pathway reducing thromboxane A₂synthesis, endothelial NO increasing platelet cGMP). In APS patients on aspirin 75–100 mg/day (particularly in obstetric APS or low-risk APS): spirulina’s additive antiplatelet effect is modest and not a concern at standard doses. In triple-positive APS on dual antiplatelet therapy (aspirin + clopidogrel) or aspirin + warfarin: the additional antiplatelet contribution from spirulina at ≥7 g/day is worth informing the treating physician about, though at 3–5 g/day it is unlikely to be clinically significant.

Drug interactions

Warfarin

• Vitamin K interaction (consistent daily dosing rule) as described above. No pharmacokinetic interaction with warfarin at CYP level. The vitamin K consistency rule is the sole practical concern at doses up to 10 g/day.

Aspirin (antiplatelet)

• Mild additive antiplatelet effect at ≥5 g/day spirulina. Not clinically significant at standard 3–5 g/day spirulina. No pharmacokinetic interaction.

Heparin / LMWH (obstetric APS)

• Heparin and LMWH (enoxaparin, dalteparin) are used in obstetric APS during pregnancy. No pharmacokinetic interaction with spirulina. No vitamin K interaction (heparins do not involve vitamin K pathway). Pregnancy safety considerations for spirulina (heavy metal CoA, no microcystin contamination) apply as in any pregnancy context.

Direct oral anticoagulants (DOACs)

• Current guidelines recommend against rivaroxaban and apixaban in APS (particularly triple-positive APS), as the TRAPS trial showed higher thrombotic events with rivaroxaban vs warfarin. If a patient is on a DOAC for APS (low-risk, single-positive): no vitamin K interaction (DOACs are not vitamin K-dependent). No pharmacokinetic interaction with spirulina.

NK stimulation in APS

• Primary APS is not autoimmune in the lymphocyte-effector sense; it is antibody and complement-mediated thrombotic disease. NK stimulation concern is low in APS not associated with SLE. In secondary APS (APS + SLE): apply the SLE NK framework (intermediate concern, discuss with rheumatologist).

Practical guidance

• APS on warfarin: inform anticoagulation clinic before starting spirulina; introduce stepwise with INR check at each step; take identical dose every day
• APS on aspirin only: spirulina 3–5 g/day appropriate; mild additive antiplatelet effect not clinically concerning; inform physician
• Obstetric APS in pregnancy: spirulina safe with LMWH; verify heavy metal CoA; vitamin K content not relevant with heparin-based anticoagulation
• Secondary APS + SLE: apply SLE NK framework; discuss with rheumatologist